Skip to main content
Premium Trial:

Request an Annual Quote

BD, HandyLab Partner on MDx Test System

NEW YORK (GenomeWeb News) — Becton Dickinson said today that it has reached an agreement to market some of its pathogen tests using HandyLab's molecular diagnostic platform.

BD said it will market its molecular diagnostic assays on a new BD MAX system, which uses Handylab's Jaguar system.

The Jaguar system incorporates clinical sample preparation, nucleic acid extraction, microfluidic real-time PCR amplification and detection. HandyLab launched the system in November 2008.

BD said it will initially focus on using its GeneOhm assays that detect pathogens responsible for hospital-acquired infections, such as its tests for methicillin-resistant staphylococcus aureus and toxigenic Clostridium difficile, in the new system.

"As our customers expand their HAI and sexually transmitted infection testing programs, they are seeking simple, flexible and fully automated systems to meet their increasing demands," Philippe Jacon, president of BD Diagnostics – Diagnostic Systems, said in a statement. "Our new BD MAX system will be a good strategic fit with our current platforms and those under development."

Financial terms of the agreement were not released.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.